Yingli Fu1, Jing Yu1, Ioanna Liatsou1, Yong Du1, Anders Josefsson1, Jessie R Nedrow1, Hans Rindt2, Jeffrey N Bryan2, Dara L Kraitchman1, George Sgouros3. 1. Department of Radiology and Radiological Science, the Johns Hopkins University School of Medicine, MD, Baltimore, USA. 2. Department of Veterinary Medicine & Surgery, the University of Missouri, Columbia, MO, USA. 3. Department of Radiology and Radiological Science, the Johns Hopkins University School of Medicine, MD, Baltimore, USA. gsgouros@jhmi.edu.
Abstract
PURPOSE: Osteosarcoma (OS) is the most frequently diagnosed bone cancer in children with little improvement in overall survival in the past decades. The high surface expression of disialoganglioside GD2 on OS tumors and restricted expression in normal tissues makes it an ideal target for anti-OS radiopharmaceuticals. Since human and canine OS share many biological and molecular features, spontaneously occurring OS in canines has been an ideal model for testing new imaging and treatment modalities for human translation. In this study, we evaluated a humanized anti-GD2 antibody, hu3F8, as a potential delivery vector for targeted radiopharmaceutical imaging of human and canine OS. METHODS: The cross-reactivity of hu3F8 with human and canine OS cells and tumors was examined by immunohistochemistry and flow cytometry. The hu3F8 was radiolabeled with indium-111, and the biodistribution of [111In]In-hu3F8 was assessed in tumor xenograft-bearing mice. The targeting ability of [111In]In-hu3F8 to metastatic OS was tested in spontaneous OS canines. RESULTS: The hu3F8 cross reacts with human and canine OS cells and canine OS tumors with high binding affinity. Biodistribution studies revealed selective uptake of [111In]In-hu3F8 in tumor tissue. SPECT/CT imaging of spontaneous OS canines demonstrated avid uptake of [111In]In-hu3F8 in all metastatic lesions. Immunohistochemistry confirmed the extensive binding of radiolabeled hu3F8 within both osseous and soft lesions. CONCLUSION: This study demonstrates the feasibility of targeting GD2 on OS cells and spontaneous OS canine tumors using hu3F8-based radiopharmaceutical imaging. Its ability to deliver an imaging payload in a targeted manner supports the utility of hu3F8 for precision imaging of OS and potential future use in radiopharmaceutical therapy.
PURPOSE: Osteosarcoma (OS) is the most frequently diagnosed bone cancer in children with little improvement in overall survival in the past decades. The high surface expression of disialoganglioside GD2 on OS tumors and restricted expression in normal tissues makes it an ideal target for anti-OS radiopharmaceuticals. Since human and canine OS share many biological and molecular features, spontaneously occurring OS in canines has been an ideal model for testing new imaging and treatment modalities for human translation. In this study, we evaluated a humanized anti-GD2 antibody, hu3F8, as a potential delivery vector for targeted radiopharmaceutical imaging of human and canine OS. METHODS: The cross-reactivity of hu3F8 with human and canine OS cells and tumors was examined by immunohistochemistry and flow cytometry. The hu3F8 was radiolabeled with indium-111, and the biodistribution of [111In]In-hu3F8 was assessed in tumor xenograft-bearing mice. The targeting ability of [111In]In-hu3F8 to metastatic OS was tested in spontaneous OS canines. RESULTS: The hu3F8 cross reacts with human and canine OS cells and canine OS tumors with high binding affinity. Biodistribution studies revealed selective uptake of [111In]In-hu3F8 in tumor tissue. SPECT/CT imaging of spontaneous OS canines demonstrated avid uptake of [111In]In-hu3F8 in all metastatic lesions. Immunohistochemistry confirmed the extensive binding of radiolabeled hu3F8 within both osseous and soft lesions. CONCLUSION: This study demonstrates the feasibility of targeting GD2 on OS cells and spontaneous OS canine tumors using hu3F8-based radiopharmaceutical imaging. Its ability to deliver an imaging payload in a targeted manner supports the utility of hu3F8 for precision imaging of OS and potential future use in radiopharmaceutical therapy.
Authors: Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton Journal: Cancer Date: 2019-07-29 Impact factor: 6.860
Authors: Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder Journal: Cancer Res Date: 2019-04-23 Impact factor: 12.701
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Michael Roth; Marissa Linkowski; John Tarim; Sajida Piperdi; Rebecca Sowers; David Geller; Jonathan Gill; Richard Gorlick Journal: Cancer Date: 2013-10-25 Impact factor: 6.860
Authors: Shakeel Modak; Jean-Benoit Le Luduec; Irene Y Cheung; Debra A Goldman; Irina Ostrovnaya; Ekaterina Doubrovina; Ellen Basu; Brian H Kushner; Kim Kramer; Stephen S Roberts; Richard J O'Reilly; Nai-Kong V Cheung; Katharine C Hsu Journal: Oncoimmunology Date: 2018-05-10 Impact factor: 8.110
Authors: Vincent I Poon; Michael Roth; Sajida Piperdi; David Geller; Jonathan Gill; Erin R Rudzinski; Douglas S Hawkins; Richard Gorlick Journal: Clin Sarcoma Res Date: 2015-01-24